Yatsenko L. D.

Platinum Preparations in the Therapy of Malignant Tumors

About the author:

Yatsenko L. D.



Type of article:

Scentific article


Chemotherapy, along with surgery and radiation therapy, is the most important concept in the therapy of cancer patients. In 1980s the significant, truly revolutionary, breakthrough in the field of cancer chemotherapy was the application of platinum preparations, antitumor activity of which was discovered in 1969. Platinum preparations, especially cys-platinum, carboplatin, considerably increased the percentage of tumors, particularly advanced ones, responding to chemotherapy. Platinum preparations (cys-platinum, carboplatin) up till now are the basic components of the majority of cancer polychemotherapy regimens, in spite of severe restrictions as for toxicity, inborn and acquired resistance of tumor cells. A crucial step forward was the creation of complexes of platinum with biopolymers in nucleophilic substitution reactions with significantly higher biocompatibility and low toxicity. Polyplatillen is the parent agent of fundamentally new class of anticancer platinum preparations, obtained pharmaceutically. The preparation has been clinically tested in two stages. Currently it is being serialized by the “Novopharm” company. Polyplatillen is mainly accumulated in tumor cells, excreted through bowels (that’s why there is no renal toxicity), does not inhibit a bone marrow hematosis. The major side effects, i. e., nausea and vomiting (10 %) are caused by enterotoxicity and are easily eliminated by current antiemetics. Short-term diarrhea, fever, allergic reactions (5 %) may be occurred. Polyplatillen is the most effective in treatment of liver tumor, lung tumor, ovarian tumor, gallbladder tumor, intestine tumor, gastric and pancreas tumor, peritoneum or pleura carcinomatosis (intraperitoneal, intra-arterial or intrapleural introduction), sarcomas and soft tissue tumor, locally advanced cancer types, having no other therapeutic perspective. Contraindications: generalization of tumor process, terminal states, severe irreversible dysfunctions of liver and kidneys. Application of polyplatillen causes stable remission in 55 % of patients, and in 35 % of cases it leads to stabilization of the process: life expectancy is increased by 1. 3 times in comparison with control group, patients’ life quality is improved, pain and manifestations of endogenous intoxication disappear, appetite and mood is ascended; patients become mobile. Patients, living not more than 6-8 months from the moment the diagnosis has been made, under the effect of polyplatillen treatment in 10-13 % of cases live more than 3-5 years under the regular recurrence of therapy courses. The preparation is rather promising as the remedy for treatment of locally advanced forms of thoracic and abdominal cavity malignant tumors. New immobilized platinum preparations are realistic and would lead to enhancement of therapeutic facilities and incensement of antitumoral effectiveness of platinum compounds.


malignant tumors, platinum preparations, polyplatillen


  • Добродеев А. А. Комбинированное лечение рака легкого с интраоперационной лучевой терапией в условиях радиосенсибилизации цисплатином : автореф. дисс. на соискание ученой степени канд. мед. наук : спец. 14.00.14 «Онкология» / А. А. Добродеев- Томск, 2004. - 19 с.
  • Кондратьев В. Б. Лечение и профилактика осложнений химиотерапии препаратами платины и таксанами / В. Б. Кондратьев, Н. А. Карасева // Практ. онкология. - 2000. - № 3. - С. 38-41.
  •  Монохіміотерапія поліплатилленом первинного раку печінки / С. О. Шалімов, О. В. Гладкий, І. І. Волченскова [та ін.] // Журн. практ. мед. - 2006. - Т. 12, № 1. - С. 22-28.
  • Орлова Р В. Современное стандартное лечение больных немелкоклеточным раком легкого с учетом стадии заболевания / Р. В. Орлова // Практ. онкол. - 2000. - № 3. - С. 17-20.
  • Переводчикова Н. И. Руководство по химиотерапии опухолевых заболеваний / Н. И. Переводчикова. - М., 2013. -511 с.
  • Полиплатиллен в монохимиотерапи первичного рака печени / С. А. Шалимов, А. А. Литвиненко, И. И. Волченскова [и др.] // Вітчизняні протипухлинні препарати : матеріали І Всеукраїн. наук. -практ. конференції, м. Київ, 14-15 жовтня 2004 р. - К., 2004. - С. 17-18.
  • Применение комбинации препаратов паклитаксела, цисплатина и фторурацила в амбулаторной химиотерапии злокачественных опухолей / Л. В. Платинский, В. В. Брюзгин, А. Г. Блюменберг [и др.] // Рос. мед. журн. - 2002. - Т. 10, № 24. - С. 1116-1118.
  • Применение полиплатиллена для лечения злокачественных новообразований IV стадии / С. А. Шалимов, Л. В. Кейсе-вич, И. И. Волченскова [и др.] // Клин. хирургия. - 1992. - № 1. - С. 40-41.
  • Результаты и перспективы применения нового химиопрепарата полиплатиллена, обладающего противоопухолевыми и противовирусными свойствами / С. А. Шалимов, Л. В. Кейсевич, И. И. Волченскова [и др.] // Клін. хірургія. - 1997. -№ 12. - С. 9-12.
  • Специфика влияния противоопухолевых соединений платины с высокомолекулярной дезоксирибонуклеиновой кислотой на выживаемость культивируемых клеток / А. А. Шалимов, С. А. Шалимов, Л. В. Кейсевич [и др.] // Доклади НАН України. - 1996. - № 3. - С. 132-137.
  • Суспензия цисплатина - активный компонент при химиоэмболизации злокачественных новообразований печени / С. А. Шалимов, А. А. Литвиненко, И. И. Волченскова [и др.] // Вітчизняні протипухлинні препарати : матеріали І Всеукраїн. наук. - практ. конф., м. Київ, 14-15 жовтня 2004 р. - К., 2004. - С. 18-19.
  • Токсические свойства отечественного противоопухолевого препарата циклоплатама / Л. И. Михайлова, Е. Л. Членова, О. И. Лоняева [и др.] // Циклоплатам. - М., 1998. - С. 16-25.
  • Шалімов С. О. Лікарська форма протипухлинного препарату та спосіб її одержання / С. О. Шалімов, І. І. Волченскова, Н. М. Майданевич // Деклараційний патент на винахід 61543 А від 17. 11.03, Бюл. № 10.
  • Шалімов С. О. Спосіб одержання комплексної сполуки платини (ІІ) з н-ДНК / С. О. Шалімов, І. І. Волченскова, Н. М. Майданев Деклараційний патент на винахід 61543 А від 17. 11.03, Бюл. № 10.
  • A phase 1 study of cis-molo-nato(4R5R)-4,5-bis(aminomethy1)-1,3-dioxolane) platinum (11) in patients with advanced malignancies / N. K. Kim, T. J. Kim, S. G. Shin [et al.] // Cancer. - 2001. - Vol. 91. - P. 1549-1556.
  • A phase II trial of gemcitabine-cisplatin-paclitaxel chemotherapy as neoadjuvant treatment of nonresectable stage IIIA (N2)
    - IIIB non-small cell lung cancer: preliminary results / F. De Marinis, F. Cappuzzo, F Nelli [et al.] // Int. J. Cancer. - 2002. -Vol. 100. - P 413.
  • A phase III trial comparing gemcitabine plus cisplatin vs gemcitabine alone in pancreatic carcinoma / V. Heinemann, D. Qui-etzsch, F Gieseler [et al.] // Proc. ASCO. - 2003. - Vol. 22. - Abstr. 1003.
  • Bang Y-J. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial / Y-J. Bang, Y-W. Kim, H-K. Yang [et al.] // Lancet. - 2012. - Vol. 379. - P 315-321.
  • Comparison of survival and quality of life in advanced non-small-cell lung cancer pftients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin : results of an Eastern Cooperative Oncology Group trial / P Bonomi, K. Kim, D. Fairclough, [et al.] // J. Clin. Oncol. - 2000. - Vol. 18. - P. 623-625.
  • Docetaxel, cisplatin, UFT and leucovorin combination chemotherapy in advanced gastric cancer / D. C. Ob, S. Sung, J. Park [et al.] // Proc. ASCO. - 2004. - Abstr. 4231.
  • Fuchs C. S. Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU/LV before and after CRT : Intergroup trial CALGB 80101 / C. S. Fuchs, J. E. Tepper, D. Niedzwiecki [et al.] // J. Clin. Oncol.
    - 2011. - Vol. 29 (suppl). - P. 256, abstr 4003.
  • Lee J. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial / J. Lee, H. Lim Do, S. Kim [et al.] // J. Clin. Oncol. - 2012. - Vol. 30. - P. 268-273.
  • Oxaliplatin (OXA), 5-fluorouracil (5-FU) and leucovorin (LV) in patients with advanced or metastatic gastric cancer / L. Cavanna, A. Zaniboni,
  • F. Artioli [et al.] // Proc. ASCO. - 2004. - Abstr. 4068.
  • Paoletti X. Benefit of Adjuvant chemotherapy for resectable gastric cancer: a meta-analysis /X. Paoletti, K. Oba, T. Burzykowsky [et al.] // JAMA. - 2010. - Vol. 303. - P. 1729-1737.
  • Phase ІІ stady of irinotecan and cisplatin in patients wity small-cell lung cancer / J. Fujiwara, M. Yamakido, M. Fukuoka [et al.] // Proc. ASCO. - 1991. - № 10. - P 189.
  • Randomised phase II trial comparing bevacizumab plus carboplatin and paclitaxel alone previously untreated locally advanced or metaststic non-small-cell lung cancer / D. H. Johnson, L. Fehrenbacker, W. F Novotny [et al.] // J. Clin. Oncol. - 2004. -Vol. 22, № 11. - P 2184-2191.
  • Sasako M. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer / M. Sasako, S. Sakuromoto, H. Katai [et al.] // J. Clin. Oncol. - 2011. - Vol. 29. - P. 43874393.
  • Smalley S. R. Updated analysis of SWOG-directed Intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection / S. R. Smalley, J. K. Benedetti, D. G. Haller [et al.] // J. Clin. Oncol. -2012. - Vol. 30. - P. 2327-2333.
  • Southwest Oncology Group. S9900: A phase III trial of surgery alone or surgery plus preoperative paclitaxel/carboplatin chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results / K. Pisters, P Bunn, J. Crowley [et al.] // ASCO Annual meeting. - 2005. - Abstr. N: LBA7012.
  • Syntesis and in vitro cytotoxicity of novel lipophilic (diamine) platinum (II) complexes of salicylate derivatives / O. S. Ye, L. G. Lou, W. P Liu [et al.] // Bioorg med Chem Lett. - 2007. - Vol. 17, № 8. - P 2146-2149.
  • Thatcher N. Some treatment concepts in SCLC / N. Thatcher // Perspectives in lung cancer : VII Europ. conf. - Athens, 2006. - P 67-73.
  • The International Adjuvant Lung Cancer Trial Collaborative Group: cisplatin-based adjuvant chemotherapy in pftients with completely resected nonsmall-cell lung cancer / R. Arriagada, B. Bergman, A. Dunant [et al.] // N. Ebgl. J. Med. - 2004. -Vol. 350, № 4. - P 351-360.
  • The International Lung Cancer Trial Collaborative Group: cisplatin based / R. Arriagada, B. Bergman, A. Dunant [et al.] // Program and abstracts of the 38th Annual Meeting of the American Society of clinical oncology; May 18-21,2002. - Orlando, Florida, 2002. - Abst. 548.
  • Toffoli G. Pharmacogenetics and stomach cancer: an update /G. Toffoli, E. Cecchin // Pharmacogenetics. - 2007. - Vol. 8, № 5. - P 497-505.

Publication of the article:

«Bulletin of problems biology and medicine» Issue 1 (106), 2014 year, 36-40 pages, index UDK 616-006. 04-085. 277. 3